Location of Trial:
Washington University School of Medicine
John L. Trotter MS Center
Name of Trial:
Arpeggio
Description:
The purpose of this study is to find out whether treatment with the investigational drug laquinimod is safe and effective in reducing the loss of brain volume and MS worsening in patients with PPMS, along with assessing the safety of the drug and determining the side effects of different dosing levels.
Participant Criteria: (age, type of MS (if necessary):
1. Age: 25 – 55
2. Diagnosis of Primary Progressive Multiple Sclerosis
3. EDSS 3-5.5 (Able to walk without aids or rest for about 100 meters)
Length of Trial:
1.5-2.5 years
Clinical Trial Sponsor:
Teva Pharmaceutical Industries Ltd.
Contact: (Name, phone #, email):
Susan Fox, Research Patient Coordinator
314-362-2017
Neurology, Campus Box 8111
660 South Euclid Ave.